Abivax Publishes 2025 Financial Calendar
28 janv. 2025 02h30 HE
|
Abivax
Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage...
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
23 janv. 2025 16h05 HE
|
Abivax
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress PARIS, France – January 23, 2025 – 10:05...
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
09 janv. 2025 11h35 HE
|
Abivax
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224...
Abivax Announces a Change to the Composition of its Board of Directors
23 déc. 2024 16h05 HE
|
Abivax
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a...
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
19 nov. 2024 16h30 HE
|
Abivax
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the...
Abivax presents third quarter 2024 key financial information
14 nov. 2024 16h01 HE
|
Abivax
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
13 nov. 2024 16h01 HE
|
Abivax
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq:...
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
07 oct. 2024 16h01 HE
|
Abivax
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00...
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
03 oct. 2024 16h01 HE
|
Abivax
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris:...
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
03 oct. 2024 02h31 HE
|
Abivax
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated...